Skip to content
2000
Volume 3, Issue 2
  • ISSN: 2212-3962
  • E-ISSN: 1574-8901

Abstract

The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD). Clopidogrel showed a similar efficacy and safety than acetylsalicylic acid (ASA). More recently, the combined use of clopidogrel with ASA has evidenced a better protection than ASA alone in some patients: patients with past history of AMI, angina pectoris, intermittent claudication or PAD, IS or TIA, coronary bypass, and diabetes mellitus, patients on treatment with statins, and patients with symptomatic carotid stenosis ≥50%. We review the reported evidence on the efficacy of clopidogrel in the secondary prevention of ischemic stroke.

Loading

Article metrics loading...

/content/journals/prc/10.2174/157489008784705340
2008-06-01
2025-08-14
Loading full text...

Full text loading...

/content/journals/prc/10.2174/157489008784705340
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test